The CXCL9 (chemokine), nerve growth factor β (β-NGF), and TNF-related apoptosis-inducing ligand (TRAIL) levels were independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after initiation of PAH therapy. Here, CXCL9 is linked to pulmonary arterial hypertension.